Aptuit LLC and Dimension Therapeutics have entered strategic partnership agreement under which Aptuit will support GLP IND-enabling studies for select rare disease programs at Dimension. Aptiut has initiated three key development projects under the alliance. Jonathan Goldman, chief executive officer, Aptuit LLC, said, “This partnership is designed to accelerate select late preclinical-stage programs at Dimension in a high-quality environment, supported by a culture of scientific excelle...